Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.48
+1.1%
$4.89
$3.42
$7.20
$251.98M1.84860,982 shs1.76 million shs
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
$1.57
-5.4%
$1.94
$1.29
$13.07
$58.99M-0.14904,454 shs1.06 million shs
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
$40.69
-1.2%
$37.43
$1.72
$54.30
$248.83M1.0534,661 shs35,807 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$2.10
+1.4%
$1.22
$0.13
$3.29
$262.42M2.048.21 million shs2.45 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
+1.13%-7.44%+0.22%-7.44%-27.15%
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-5.42%-14.21%-4.85%-27.98%-71.81%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-1.19%-9.52%+15.73%-9.50%+1,095.01%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
+1.45%-4.55%+44.83%+217.51%+126.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.3662 of 5 stars
0.03.00.00.00.60.80.6
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
3.1102 of 5 stars
3.63.00.00.03.02.50.6
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1.944 of 5 stars
3.43.00.00.00.62.50.0
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
3.2667 of 5 stars
4.30.00.00.03.21.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
3.18
Buy$20.101,180.25% Upside
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
2.83
Moderate Buy$60.0047.46% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.60
Moderate Buy$5.63168.03% Upside

Current Analyst Ratings Breakdown

Latest BMEA, MNPR, VOR, and ACB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
7/16/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$22.00 ➝ $9.00
7/7/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$74.00
6/30/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$3.00
6/26/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Outperform
6/24/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/23/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
6/13/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/3/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$7.00
6/2/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/15/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M1.02$0.61 per share7.33$7.78 per share0.58
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/A$1.42 per shareN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/A$9.02 per shareN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M$0.1140.7310.18N/A1.32%0.13%0.10%8/6/2025 (Estimated)
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$138.43M-$3.55N/AN/AN/AN/A-197.71%-134.84%N/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$15.59M-$3.48N/AN/AN/AN/A-55.39%-51.53%8/8/2025 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/A-$1.51N/AN/AN/AN/AN/AN/AN/A

Latest BMEA, MNPR, VOR, and ACB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025N/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.47N/AN/AN/AN/AN/A
8/6/2025Q1 2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.18N/AN/AN/A$96.83 millionN/A
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
5/13/2025Q1 2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.65-$0.38+$0.27-$0.38N/AN/A
5/5/2025Q1 2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$0.84-$0.80+$0.04-$0.80N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.13
4.31
2.16
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/A
2.25
2.25
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/A
36.91
36.91
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
96.72%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1.83%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
18.42%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
20.50%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.25 million56.24 millionOptionable
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
5037.57 million30.65 millionOptionable
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
106.12 million4.86 millionNot Optionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
140124.96 million65.45 millionNot Optionable

Recent News About These Companies

Analysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $5.63
Vor Biopharma (NYSE:VOR) Trading Down 2.9% - Time to Sell?
Vor Biopharma Announces Key Leadership Changes

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.48 +0.05 (+1.13%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$4.49 +0.01 (+0.22%)
As of 08/1/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Biomea Fusion stock logo

Biomea Fusion NASDAQ:BMEA

$1.57 -0.09 (-5.42%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.64 +0.07 (+4.71%)
As of 08/1/2025 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Monopar Therapeutics stock logo

Monopar Therapeutics NASDAQ:MNPR

$40.69 -0.49 (-1.19%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$40.56 -0.13 (-0.31%)
As of 08/1/2025 04:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Vor Biopharma stock logo

Vor Biopharma NYSE:VOR

$2.10 +0.03 (+1.45%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.04 -0.06 (-2.86%)
As of 08/1/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.